We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $118M
This Fund
S&P 500
This Quarter Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
Cap. Flow
-$34.7M
Cap. Flow %
-23.28%
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$2.73M
2
PFE icon
Pfizer
PFE
+$2.42M
3
ARGX icon
argenx
ARGX
+$2.33M
4
VYNE icon
VYNE Therapeutics
VYNE
+$2.08M
5
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$1.95M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$3.38M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$2.95M
3
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$2.75M
4
TSVT
2seventy bio
TSVT
+$2.58M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 59.47%
2 Real Estate 11.94%
3 Financials 4.93%
4 Consumer Discretionary 2.41%
5 Industrials 2.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVAV icon
226
AeroVironment
AVAV
$7.57B
– –
-9,000
Closed -$1M
AZO icon
227
AutoZone
AZO
$48.3B
– –
-89
Closed -$226K
BCYC
228
Bicycle Therapeutics
BCYC
$270M
– –
-58,500
Closed -$1.18M
BMY icon
229
Bristol-Myers Squibb
BMY
$127B
– –
-3,153
Closed -$183K
BWA icon
230
BorgWarner
BWA
$13.2B
– –
-2,246
Closed -$90.7K
CF icon
231
CF Industries
CF
$19.2B
– –
-1,150
Closed -$98.6K
CLDX icon
232
Celldex Therapeutics
CLDX
$2.77B
– –
-15,000
Closed -$413K
CNQ icon
233
Canadian Natural Resources
CNQ
$96.9B
– –
-3,172
Closed -$103K
COLL icon
234
Collegium Pharmaceutical
COLL
$1.14B
– –
-49,500
Closed -$1.11M
COP icon
235
ConocoPhillips
COP
$147B
– –
-2,162
Closed -$259K
CRNX icon
236
Crinetics Pharmaceuticals
CRNX
$8.86B
– –
-82,000
Closed -$2.44M
CTRA
237
DELISTED
Coterra Energy
CTRA
– –
-9,731
Closed -$263K
CVE icon
238
Cenovus Energy
CVE
$54.6B
– –
-7,003
Closed -$146K
CVX icon
239
Chevron
CVX
$388B
– –
-1,195
Closed -$202K
DAWN
240
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-95,000
Closed -$1.17M
DINO icon
241
HF Sinclair
DINO
$15.9B
– –
-1,699
Closed -$96.7K
DVN icon
242
Devon Energy
DVN
$51.9B
– –
-697
Closed -$33.2K
ENPH icon
243
Enphase Energy
ENPH
$4.84B
– –
-137
Closed -$16.5K
EOG icon
244
EOG Resources
EOG
$78B
– –
-1,036
Closed -$131K
EXEL icon
245
Exelixis
EXEL
$13.9B
– –
-30,000
Closed -$656K
FANG icon
246
Diamondback Energy
FANG
$57.6B
– –
-860
Closed -$133K
GL icon
247
Globe Life
GL
$13.5B
– –
-2,074
Closed -$226K
GMED icon
248
Globus Medical
GMED
$10.4B
– –
-10,000
Closed -$497K
GPC icon
249
Genuine Parts
GPC
$17.1B
– –
-1,362
Closed -$197K
HCA icon
250
HCA Healthcare
HCA
$84.8B
– –
-390
Closed -$95.9K
8 9
10
11 12

Similar funds

AIS
Advocate Investing Services Woodbine, Maryland $118M AUM
IVGAI
Index Venture Growth Associates III St. Helier, Channel Islands, Jersey $118M AUM 64.91% 1-Year Est. Return
OIM
Oceanic Investment Management Douglas, Isle Of Man $118M AUM
TIP
Tandem Investment Partners Bordentown, New Jersey $118M AUM 15.76% 1-Year Est. Return
RCG
Ridge Creek Global Strongsville, Ohio $118M AUM
CWM
Capstone Wealth Management Billings, Montana $118M AUM
SPW
Stillwater Private Wealth Glen Mills, Pennsylvania $118M AUM
WLC
Walnut Level Capital Denver, Colorado $118M AUM 59.12% 1-Year Est. Return

AlphaCentric Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.

  • AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
  • AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
  • AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
  • AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
  • AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
  • AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
  • AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.